Chromobacterium violaceum ATCC12472: Multi-drug and ethidium bromide resistant by Cristiana G. O. Dal&#x27 et al.
 1
Chromobacterium violaceum ATCC12472: Multi-drug 1 
and ethidium bromide resistant 2 
 3 
Cristiana Gomes de Oliveira1, Regina Vasconcellos Antônio2, Luismar Marques Porto3. 4 
1,3Genome Engineering Group, Universidade Federal de Santa Catarina, Caixa Postal 476, 5 
CEP 88040-900, Florianópolis-SC, Brazil, cristiana_go@hotmail.com, luismar@enq.ufsc.br; 6 
2Department of Biochemistry, Universidade Federal de Santa Catarina, Caixa Postal 476, CEP 7 
88040-900, Florianópolis-SC, Brazi, rantonio@mbox1.ufsc.br. 8 
                                                 
1 Correspondent author/Current address: 
 Cristiana Gomes de Oliveira, Australian Institute for Bioengineering and Nanotecnology, Telephone 





































Chromobacterium violaceum is an opportunistic human pathogen causing a range of gastric 11 
infections and occasionally septicemia. This Gram-negative bacillus is a common inhabitant of 12 
soil and water in tropical and subtropical areas of the world. Infection occurs after contamination 13 
of damaged skin exposed to soil or environmental water. Alternatively, systemic infection can 14 
follow the aspiration or ingestion of contaminated water. The major features of infections by C. 15 
violaceum are, in generally, rapid clinical course, multiple visceral abscesses, and high 16 
mortality. Genomic data on the type strain ATCC 12472 has provided a comprehensive basis for 17 
detailed studies of pathogenicity, virulence and drug resistance genes. In this study, the 18 
susceptibility of this organism was tested on a variety of drugs at different concentrations, in 19 
solid and liquid media. C. violaceum shown to be resistance to ampicilin, penicillin, rifampicin, 20 
erythromycin, vancomycin and also to ethidium bromide. The bacteria was susceptible to 21 
gentamicin, tetracycline, chloramphenicol, cotrimoxazole, kanamycin, streptomycin and nalidixic 22 
acid, at the tested concentrations. 23 





































Chromobacterium violaceum is a common inhabitant of soil and water in tropical and sub-27 
tropical regions. This Gram negative bacillus is considered as a saprophyte, but occasionally it 28 
can act as an opportunistic pathogen for animals and man (Crosse et al. 2006; Fombuena et al. 29 
1998; Hassan et al. 1993; Ti et al. 1993).  In immunocompromised individual the localized lesion 30 
might lead to septicaemic infections with abscesses in multiple internal organs, urinary tract 31 
infection and diarrhoea. The most common feature of this infection is sepsis, followed by 32 
cutaneous involvement and liver abscesses (Midani & Rathore, 1998). Lung abscesses have 33 
also been reported (Sirinavin et al. 2005; Tee et al. 2006; Teoh et al. 2006). Mortality rate is 34 
very high for patients with disseminated infections (Ang, 2004). The first case in humans was 35 
reported in Malaysia in 1927, and the medical literature contains reports of approximately 150 36 
human cases since then (Midani & Rathore, 1998; Ray et al. 2004; Teoh et al. 2006). This 37 
bacteria is able  to compete with other bacteria in the environment and possess a highly 38 
effective survival mechanism (Brito et al. 2004; Duran & Menck, 2001). Infection treatment is 39 
very difficult and currently there are no vaccines. A successfully treatment with ciprofloxacin and 40 
amikacin has been reported (Ray et al. 2004).  41 
The resistance of prokaryotic organisms to many unrelated hydrophobic 42 
chemotherapeutic drugs is termed multi-drug resistance (MDR). A variety of MDR efflux 43 
systems are widely distributed among prokaryotic microorganisms, including pathogenic 44 
bacteria (Aeschlimann, 2003; Lewis, 1994; Lewis et al. 1994; Marquez, 2005). They belong to 45 
three different families of transport proteins: the major facilitator superfamily (MFS) (Saidijam et 46 
al. 2006; Vardy et al. 2004), the resistance nodulation division (RND) family (Gotoh et al. 1999; 47 
Piddock, 2006; Saier et al. 1994), and the small multidrug resistance (SMR) family of small 48 
translocases (Jack et al. 2000; Paulsen et al. 1996; Tate, 2006). 49 
Genomic data of C.violaceum ATCC 12472 (http://www.brgene.lncc.br/cviolaceum/) has 50 
provided a comprehensive basis for detailed studies of pathogenicity, virulence and drug 51 
resistance genes (Brito et al. 2004; Fantinatti-Garboggini et al. 2004). The genome contains 52 
extensive but incomplete arrays of ORFs coding for proteins associated with mammalian 53 



































infection (Consortium, 2003). In this study, we provided experimental data of drug resistance of 55 
C. violaceum ATCC12472 on a variety of antibiotics, in different concentrations, in solid and 56 
liquid media. Ethidium bromide was also tested, in order to confirm the resistance to this toxic 57 
compound, as indicated by the genome data. 58 
 59 
Material and Methods 60 
 61 
Chromobacterium violaceum ATCC12472 was grown for 12 hours on shaking in Luria 62 
Bertani (LB) broth medium and in LB agar plates at 30oC. For the susceptibility assay, fourteen 63 
different drugs, including ethidium bromide, were tested at different concentrations when C. 64 
violaceum were cultivated in liquid and in solid LB medium. Antimicrobial susceptibility was also 65 
tested using plate disc diffusion method. Experiments were repeated on triplicates and shown 66 
agreement. 67 
  68 
Results 69 
Chromobacterium vioalceum ATCC12472 strain is resistant to a variety of antibiotics and 70 
is also resistant to ethidium bromide, as shown in Tables 1-3. This organism is more sensitive to 71 
gentamycin and tetracycline at concentrations higher than 10μg/ml. It is very resistant to 72 
rifampicin, vancomicin, and ampicilin, even at concentrations higher than 130μg/ml. This strain 73 
was found sensitive to erythromycin at concentration higher than 50μg/ml when it was cultivated 74 
in LB broth. However, in LB agar plates it was resistant to erythromycin at concentrations higher 75 
than 130μg/ml.  76 
 77 
Discussion 78 
Chromobacterium violaceum ATCC12472, a wild type strain, showed to be resistant to 79 
ethidium bromide even at concentrations higher than 50μg/ml. It has been reported that 80 
mutantes of Baciluus subtilis was found to be resistant to 10 μg of ethidium bromide per ml 81 
(Bishop & Brown, 1973). E-coli mutants have been reported to be resistant to ethidium bromide 82 
at concentration higher than 75μg/ml, when mdfA was over-expressed. MdfA is a putative 83 



































are a large number of open reading frames associated with various mechanisms of drug 85 
resistance in the C. violaceum genome. Genes associated with bacitracin, bicyclomycin, 86 
chloramphenicol, kasugamycin, and methylenomycin were also found (Fantinatti-Garboggini et 87 
al. 2004), comprising a remarkable feature of this organism. Families of drug extrusion 88 
translocases have been identified in the C. violaceum genome, based on sequence homology. 89 
These are the MFS (major facilitator super family), SMR (small multidrug resistance), RND 90 
(resistance nodulation cell division), ABC (ATP-binding cassette), and MATE (multidrug and 91 
toxic compound extrusion) family (Fantinatti-Garboggini et al. 2004). EmrE, the product of the 92 
emrE gene homolog identified in the C. violaceum genome is an SMR-related protein. The most 93 
striking feature of EmrE is that it is capable of transporting substrates of widely varying 94 
structure, provided that overall the compound is highly hydrophobic and carries a positive 95 
charge. EmrE couples the extrusion of toxins to the influx of protons down their electrochemical 96 
gradient, with probably two or more protons transported per toxin molecule (Arkin et al. 1996; 97 
Lebendiker & Schuldiner, 1996; Schuldiner et al. 1996; Venkatraman et al. 2002; Yerushalmi et 98 
al. 1996). Presence of a large number of open reading frames associated with various 99 
mechanisms in C. vioalceum genome may help to explain the resistance of this organism to 100 
ethidium bromide and to a variety of antibiotics tested. 101 
 102 
Conclusion 103 
In this study, we have tested drug resistance of C. violaceum ATCC12472 strain at 104 
different concentrations of different antibiotics. C. violaceum is resistance to a wide broad range 105 
of antibiotics, and was found to be resistant to ethidium bromide at concentrations higher than 106 
50μg/ml. The presence of multi-drug resistance genes found in C. violaceum genome may 107 
explain such ability to survive, and may represents a challenging for infection treatment. 108 
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Table 1. Test of Antibiotics resistance to Chromobacterium 230 









 Ampicilin 10 + 
 Penicilin 10 + 
 Gentamicin 10 - 
 Tetracycline 30 - 
 Chloramphenicol 30 - 
Cotrimoxazole 25 - 



































Table 2. Test of antibiotics resistance to Chromobacterium violaceum (ATCC12472) in solid 233 





*Susceptibility of  
C. violaceum ATCC12472 
Rifampicin 10 + 
 20 + 
 30 + 
 50 + 
 100 + 
 150 + 
 200 + 
Erythromycin 50 + 
 100 + 
 150 + 
Ethidium bromide 10 + 
 15 + 
 20 + 
 25 + 
 40 + 



































Table 3. Test of antibiotics resistance to Chromobacterium 236 






*Susceptibility of  
C. violaceum ATCC12472 
Ampicilin 50 + 
 100 + 
 150 + 
Tetracycline 10 - 
Kanamycin 50 - 
Chloramphenicol 50 - 
Streptomycin 50 - 
Nalidixic Acid 15 - 
Vancomycin 50 + 
 75 + 
 100 + 
 150 + 
Erythromycin 50 + 
 75 - 
 100 - 
 150 - 
Rifampicin 50 + 
 100 - 
 150 - 
 200 - 
Carbamycin 20 + 
 50 + 
 100 - 
 150 - 
Ethidium bromide 1 + 
 10 + 
 30 + 
 60 + 
* (+) Resistant; Sensitive(-). 238 
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